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In addition to the free radical form of nitric oxide (NO•),
the reduced form of NO (NO-/HNO) is also produced
endogenously, causes vasorelaxation and has therapeutic
potential in the treatment of heart failure. Given we have
shown previously that, unlike the NO• donor glyceryl trin-
itrate (GTN), the HNO donor Angeli's salt (AS) does not
develop tolerance in vitro [1], this study aimed to deter-
mine whether AS was also resistant to the development of
tolerance in vivo. Initial experiments using WKY rats con-
firmed that infusion with the HNO scavenger, N-Acetyl-L-
cysteine (6.7 μmol/kg/min) significantly (P < 0.0001)
attenuated the concentration dependent depressor
responses to AS, whilst those to GTN or the additional
NO• donor, DEA/NO, were unchanged. Rats were instru-
mented with arterial and venous catheters and the depres-
sor effects of GTN, AS and DEA/NO were examined in
vehicle treated and GTN (10 μg/kg/min), AS (20 μg/kg/
min) or DEA/NO (2 μg/kg/min) pre-treated animals (3
day infusion via osmotic mini pump). Following this, aor-
tae were removed and ex vivo tolerance to all vasodilators
assessed via examining vasorelaxation responses. GTN
pre-treatment significantly blunted the depressor
response to 50 μg/kg GTN (-9 ± 1 mmHg MAP) compared
to vehicle treated rats (-40 ± 2 mmHg MAP; n = 8–9; P <
0.001) but did not alter the depressor responses to either
AS or DEA/NO. Similarly, in vitro relaxation responses to
GTN in GTN pre-treated rats showed a significant 6-fold
decrease in sensitivity (pEC50 = 6.72 ± 0.23; Rmax = 79.4 ±
3.4%; n = 7) compared with vehicle treated rats (pEC50 =
7.51 ± 0.14; Rmax= 93.4 ± 2.1%; n = 6; P < 0.05) yet vasore-
laxation to AS and DEA/NO was unchanged. In addition,
vasorelaxation to acetylcholine (ACh) was attenuated in
GTN pre-treated rats (Rmax = 54.4 ± 5.4%; n = 6) compared
to vehicle treated rats (Rmax = 77.1 ± 2.3%; n = 5). In con-
trast, AS was resistant to in vivo tolerance development.
Thus the depressor response to 200 μg/kg AS (-33 ± 4
mmHg MAP; n = 6–7) was unchanged following AS pre-
treatment (-34 ± 3 mmHg MAP). Furthermore AS did not
cause cross tolerance to either GTN or DEA/NO in vivo.
Likewise, there was no change in the in vitro relaxation
responses to AS in AS pre-treated rats (pEC50 = 6.77 ± 0.15;
Rmax = 92.3 ± 1.7%; n = 7) compared with vehicle treated
rats (pEC50 = 6.77 ± 0.17; Rmax = 93.0 ± 2.7%; n = 6), nor
was there a reduced response to ACh. Like AS, DEA/NO
did not develop tolerance either in vitro or in vivo. In con-
clusion, the HNO donor AS does not develop tolerance in
vivo, thus suggesting that HNO donors may represent a
novel class of nitrovasodilator for the treatment of cardio-
vascular disorders, such as heart failure and angina.
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